Posted On: 10/06/2015 11:46:51 PM
Post# of 72446
Here's the AVXL hit piece:
Kind of sounds like they hired Mako to write the hit piece, doesn't it? Note that they promise that they're going to attack more development stage biotechs, which by their nature do not make money, they lose money developing drugs which may eventually save the lives of the scumbags trying to take them down.
Quote:
The StreetSweeper issues a negative report on AVXL.
From the report:
The New York company has no commercial product, hasn't earned a penny since inception ~12 years ago, has lost $61.8 million, yet pulls down an astonishing $230 million market cap. Meanwhile, Anavex pays its CEO millions and sits on the edge of conducting a dilutive stock offering. We're just scratching the surface with this first look at a batch of highly promotional biotech stocks poised to dive.
Kind of sounds like they hired Mako to write the hit piece, doesn't it? Note that they promise that they're going to attack more development stage biotechs, which by their nature do not make money, they lose money developing drugs which may eventually save the lives of the scumbags trying to take them down.
(0)
(0)
